Sandoz and its generic Remodulin (treprostinil) partner Liquidia have welcomed a US court opinion that concluded the firms suffered losses of more than $137m as a result of interference by originator United Therapeutics in the launch of the generic treatment for pulmonary arterial hypertension.
Sandoz And Liquidia Triumph On Treprostinil
Court Finds Pair Suffered Losses Of More Than $137m From United Therapeutics Block
Sandoz and partner Liquidia have welcomed a US court decision which found that interference by United Therapeutics with the launch of their generic treprostinil injection rival to Remodulin caused the pair losses of more than $137m.
More from Legal & IP
• By
Teva will have to delist its ProAir HFA inhaler patents from the FDA’s Orange Book by mid-March, as the Federal Circuit denied its petition for en banc rehearing. Will the Supreme Court listen?
• By
Sandoz CEO Richard Saynor has spoken of his frustration at a lawsuit from J&J seeking to prevent the launch of a private-label ustekinumab biosimilar in the US, which he described as “the desperate actions of an originator trying to protect its market.”
• By
The US Association for Accessible Medicines says it is looking to “protect the public’s interests in ensuring that patents do not let inventors control more than they invented,” as it moved to file in support of MSN Laboratories’ legal tussle with Novartis over a key patent shielding the originator’s $7.8bn Entresto blockbuster.
• By
The same day as Samsung Bioepis and Sandoz launched their partnered Pyzchiva biosimilar rival to Stelara in the US, originator J&J hit the Korean developer with a lawsuit claiming that a private-label commercialization deal with a US pharmacy benefit manager violates the ustekinumab settlement that allowed the firms to launch.
More from Generics Bulletin
Sponsored by:
Delve into the challenges facing the NHS, from rising medicine costs to supply shortages, and how generics and branded generics can provide solutions for a more sustainable healthcare system
• By
Eyeing the lucrative opportunity, three Indian players have launched their generic versions of Boehringer’s anti-diabetes drug Jardiance in their domestic market.
• By
Celltrion has become the latest firm to enter the competitive US market for Stelara biosimilars, revealing details of its Steqeyma launch.